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The US FDA currently accepts carcinogenicity studies of 
pharmaceutical drugs based on murine models. In addition to 6 month 
studies with p53(+/-) and ras.H2 transgenic mice, lifetime studies 
(typically 2 years) in WT mice or rats are also considered as evidence 
that a drug lacks carcinogenic activity. This model is not always 
exhaustive. For example, during the acceptance testing of the ARB 
Olmesartan[1], possible carcinogenicity observed in hamsters was not 
able to be duplicated in rats, or in transgenic mice. We have previously 
used the static molecular modeling of AutoDock to demonstrate that 
Olmesartan has agonostic activity in the PDB:1DB1 model of the 
human VDR Nuclear Receptor[2], while it has antagonistic activity in 
the PDB:1RK3 model of the rat VDR. This agonism has now been 
confirmed with Molecular Dynamics, using GROMACS. The murine 
VDR indeed lost its ability to bind the DRIP 205 co activator when 
Olmesartan was the ligand, while the human VDR was activated by 
Olmesartan similarly to its native ligand (1,25-dihydroxyvitamin-D). 
Since the VDR is believed to express 913 genes[3], many of which are 
known to be associated with cancer pathogenesis, good homology 
between human VDR, and the animal model VDR, is exceedingly 
important.
CONCLUSION: The murine environment is inadequate to accurately 
model drug carcinogenic activity in humans. A species should be 
chosen which has a VDR LBP homology closer to that of man. AutoDock 
and GROMACS molecular analyses are useful in resolving any 
remaining anomalies in the observed data.
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Plots of inter-molecular atomic contacts make it easy to see that 1,25-
dihydroxyvitamin-D binds symmetrically into the VDR from both 
Homo sapiens and Rattus norvegicus, yet the conformation of chemical 
ligands is different, due to lack of VDR homology.
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This video was created using the GROMACS Molecular 
Dynamics software on a small computing cluster assembled 
from PCs based on Core-2-duo CPU technologies. The 
difference in steady-state ligand conformation between 
human and rat VDR can clearly be seen at 
http://autoimmunityresearch.org/dmm2007/dmm2007.ram
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Plots of the instantaneous number of hydrogen bonds 
compiled during the molecular dynamics simulations 
show surprising similarities, and differences, between 
the behavior of the Olmesartan-VDR complexes.
Analysis of the rat VDR and DRIP205 model (PDB:1RK3) 
show that the activation of the VDR is only partly due to 
the AF-2 domain. There are hbonds from GLU416 to 
DRIP MET629/LEU630, but there are also hbonds from 
LYS260 to HIS627, and LYS242 to LEU633.
Human Rat
Four hydrogen bonds
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